Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis

González-Blanco L. ; García-Portilla M.P. ; Gutiérrez M. ; Mezquida G. ; Cuesta M.J. ; Urbiola E. ; Amoretti S. ; Barcones F. (Universidad de Zaragoza) ; González-Pinto A. ; Pina-Camacho L. ; Corripio I. ; Vieta E. ; Baeza I. ; Toll A. ; Sáiz P.A. ; Bobes J. ; Bernardo M. ; Bioque M. ; Sagué M. ; Alonso-Solís A. ; Grasa E. ; González-Ortega I. ; Zorrilla I. ; Santabárbara J. (Universidad de Zaragoza) ; De-la-Cámara C. (Universidad de Zaragoza) ; Aguilar E.J. ; Nacher J. ; Bergé D. ; Mané A. ; Montejo L. ; Anmella G. ; Castro-Fornieles J. ; de la Serna E. ; Contreras F. ; Sáiz-Masvidal C. ; García-Álvarez L. ; Bobes-Bascarán T. ; Zabala-Rabadán A. ; Segarra-Echevarría R. ; Sanchez-Pastor L. ; Rodriguez-Jimenez R. ; Usall J. ; Butjosa A. ; Sarró S. ; Guerrero-Pedraza A. ; Ibañez Á. ; Ribeiro M. ; Balanzá-Martínez V. ; PEPs Group

Resumen: Objective: There is high prevalence of cigarette smoking in individuals with first-episode psychosis (FEP) prior to psychosis onset. The purpose of the study was to determine the impact of previous tobacco use with or without cannabis on first psychotic experiences in FEP and the impact of this use on age of onset of symptoms, including prodromes. Methods: Retrospective analyses from the naturalistic, longitudinal, multicentre, “Phenotype-Genotype and Environmental Interaction. Application of a Predictive Model in First Psychotic Episodes (PEPs)” Study. The authors analysed sociodemographic/clinical data of 284 FEP patients and 231 matched healthy controls, and evaluated first psychotic experiences of patients using the Symptom Onset in Schizophrenia Inventory. Results: FEP patients had significantly higher prevalence of tobacco, cannabis, and cocaine use than controls. The FEP group with tobacco use only prior to onset (N = 56) had more sleep disturbances (42.9% vs 18.8%, P = 0.003) and lower prevalence of negative symptoms, specifically social withdrawal (33.9% vs 58%, P = 0.007) than FEP with no substance use (N = 70), as well as lower prevalence of ideas of reference (80.4% vs 92.4%, P = 0.015), perceptual abnormalities (46.4% vs 67.4%, P = 0.006), hallucinations (55.4% vs 71.5%, P = 0.029), and disorganised thinking (41.1% vs 61.1%, P = 0.010) than FEP group with previous tobacco and cannabis use (N = 144). FEP patients with cannabis and tobacco use had lower age at first prodromal or psychotic symptom (mean = 23.73 years [SD = 5.09]) versus those with tobacco use only (mean = 26.21 [SD = 4.80]) (P = 0.011). Conclusions: The use of tobacco alone was not related to earlier age of onset of a first psychotic experience, but the clinical profile of FEP patients is different depending on previous tobacco use with or without cannabis. © 2021 The Authors

Idioma: Inglés

DOI: 10.1016/j.schres.2021.07.017

Año: 2021

Publicado en: SCHIZOPHRENIA RESEARCH 236 (2021), 19-28
ISSN: 0920-9964

Factor impacto JCR: 4.662 (2021)

Categ. JCR: PSYCHIATRY rank: 64 / 157 = 0.408 (2021) - Q2 - T2
Categ. JCR: PSYCHIATRY rank: 47 / 144 = 0.326 (2021) - Q2 - T1

Factor impacto CITESCORE: 8.0 - Neuroscience (Q1) - Medicine (Q1)

Factor impacto SCIMAGO: 1.451 - Psychiatry and Mental Health (Q1) - Biological Psychiatry (Q1)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)
Área (Departamento): Área Medic.Prevent.Salud Públ. (Dpto. Microb.Ped.Radio.Sal.Pú.)